FDA WARNING_LETTER - Ad-Tech Medical Instrument Corporation - January 11, 2012

The FDA issued a Warning Letter to Ad-Tech Medical Instrument Corporation following an inspection from December 2011 to January 2012, which found their neurological monitoring and neurosurgery devices adulterated under section 501(h) of the Federal Food, Drug, and Cosmetic Act. The firm's manufacturing methods, facilities, and controls were not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation, 21 CFR Part 820. Key violations include failures to establish adequate procedures for design change (21 CFR 820.30(i)), design review (21 CFR 820.30(e)), corrective and preventive action (21 CFR 820.100(a)), rework of nonconforming product (21 CFR 820.90(b)(2)), changes to specifications and procedures (21 CFR 820.70(b)), and control of nonconforming product (21 CFR 820.90(a)). Additionally, the firm failed to adequately document and approve process validation activities and results (21 CFR 820.75(a)). The FDA noted that some corrective actions were incomplete or not fully assessed for effectiveness. The company must promptly correct these violations and respond within 15 working days with a detailed plan, including documentation and a timetable. Failure to comply could result in regulatory actions such as seizure, injunction, civil money penalties, and impact premarket approvals and Certificates to Foreign Governments. The letter emphasizes that these observations may indicate broader issues within the firm's quality assurance systems.